About ViroForce
ViroForce Systems Inc. has developed an innovative and cost-effective solution to the growing and costly problem of disinfecting rooms in cruise ships, long-term health care facilities, hospitals, medical clinics, hotels and other spaces susceptible to the numerous devastating viruses and bacteria that are becoming a daily global occurrence. Laboratory and in-field tests (third-party test – MRSA and Norovirus to date) have proven that ViroForce can effectively disinfect and eradicate: Calicivirus, Norovirus, Corona Virus, Influenza Virus, H1N1, Rhinovirus, Poliovirus, Herpes Simplex Virus, C. Difficile and MRSA (Methicillin-resistant Staphylococcus Aureus) and numerous other bacteria and fungi.
Eliminates Viruses and Bacteria
ViroForce has demonstrated in laboratory experiments that it can kill more than 99.9% of each of the following viruses:
- Calicivirus (feline strain, a relative of the Norovirus)
- Norovirus
- Corona virus (mouse strain, a relative of the SARS virus)
- Influenza virus (related to H1N1)
- Rhinovirus (common cold virus)
- Poliovirus
- Herpes Simplex virus
ViroForce Systems has also demonstrated the technology is effective against C. difficile and MRSA (Methicillin-resistant staphylococcus Aureus) and numerous other bacteria and fungi. It can also be used in disinfecting against the H5N1 Avian flu, should it mutate to create a human flu pandemic.
Problems in Hospitals
The cost to hospitals alone in North America and the United Kingdom is more than US$21B per annum.
| Country |
No. of Hospitals. |
Annual Cost US$ |
| United States |
5,200 |
$ 12.37 B |
| Canada |
1,200 |
$ 2.80 B |
| United Kingdom |
2,500 |
$ 5.95 B |
| TOTAL COST |
$ 21.12 B |
If the ViroForce technology were implemented, it is anticipated savings would be over US$9.3B per annum. The company has received written notification from the US FDA that registration for the sale of the product into the US health care industry is not required.
Contact us for more about our disinfection and odor elimination service
